No annual revenue total was found in Generate Biomedicines, Inc.'s SEC filings.
Generate Biomedicines, Inc. (GENB) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $457.4 million in cash and investments and $62.6 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$394.79M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GENB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Somerville, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2100782
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Aug 26, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 2, 2026 | Feb 26, 2026 |
All 56 Generate Biomedicines, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.